Overview Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis Recent advances in leukotriene B4 receptor antagonist research

References

• FORD-HUTCHINSON AW: Leukotriene B4 in inflamma-tion. Crit. Rev. Immunol. (1990) 10:1–12.
   PubMed Web of Science ®Google Scholar
• MCMILLAN RM, FOSTER SJ: Leukotriene B4 and inflam-matory disease. Agents Actions (1988) 24:114–119.
   PubMedGoogle Scholar
• SHARON P, S'TENSON WF: Enhanced synthesis of leukotriene ft4 by colonic mucosa in inflammatory bowel disease. Gastroenterology(1984) 86:453-460. The seminal work implicating LTB4 in IBD.
   Google Scholar
• BARR RM, WONG E, MALLET Al, OLINS LA, GREAVES MW: The analysis of arachidonic acid metabolites in normal, uninvolved and lesional psoriatic skin. Prostaglandins (1984) 28:57–65.
   PubMedGoogle Scholar
• THOFtSEN S, FOGH K, BROBY-JOHNSEN U, SONDER-GAARD J: Leukotriene B4 in atopic dermatitis: increased skin levels and altered sensitivity of peripheral blood T-cells. Allergy (1990) 48:457–463.
   Google Scholar
• SHINDO K, MATSUMOTO Y, HIRAI Y et al.: Measurement of leukotriene B4 in arterial blood of asthmatic patients during wheezing attacks. J. Int. Med. (1990) 228:91–96.
   PubMedGoogle Scholar
• AHMADZADEN N, SHINGU M, BOBUNAGA M, TOWARA T: Relationship between leukotriene B4 and immunologi-cal parameters in rheumatoid synovial fluids. Inflam-mation (1991) 15:497–503.
   PubMedGoogle Scholar
• RAE SA, DAVIDSON EM, SMITH MJH: Leukotriene B4, an inflammatory mediator in gout. Lancet (1982) 2:1122.
   PubMed Web of Science ®Google Scholar
• KLICKSTEIN LB, SHAPLEIGH L, GOETZL E: Lipoxygena-tion of arachidonic add as a source of PMN leucocyte chemotactic factors in synovial fluids and tissue in rheumatoid arthritis and spondyloarthritis. J. Clin. Invest. (1980) 66:1166–1170.
   PubMed Web of Science ®Google Scholar
• HARRIS RR, CARTER GW, BELL EL, MOORE JL, BROOKSCDW: Clinical activity of leukotriene inhibitors. Int. J. Immunopharmac. (1995) 17:147–156.
   PubMed Web of Science ®Google Scholar
• MCMILLAN RM, WALKER ERH: Designing effective 5-lipoxygenase inhibitors. Trends Pharmacol, Sci. (1992) 13:323–330.
   PubMed Web of Science ®Google Scholar
• BAIT DG: S-Lipoxygenase inhibitors and their anti-in-flammatory activities. Frog. Med. Chem. (1992) 29:1–63.
   PubMedGoogle Scholar
• DJURIC SW, FRETLAND DJ, PENNING TD: The leukotriene 134 receptor antagonists - a most discriminating class of anti-inflarnmatory agents? Drugs Fut. (1992) 17:819–830.
   Google Scholar
• COHEN N, YAGALOFF KA: Recent progress in the devel-opment of LTB4 receptor antagonists. Curr. Opin. Invest. Drugs (1994) 3:13–22.
   Google Scholar
• ELSON CO, SARTOR RB, TENNYSON GS, RIDDELL RH:
   Google Scholar
• • Experimental models of inflammatory bowel disease. Gastroenterology (1995) 109:1344-1367. Fine summary of the relevant animal models.
   Google Scholar
• BERTRAN X, MANE J, FERNANDEZ BANARES F, CASTELLAE, BARTOLI R, OJANGUREN I, ESTEVE M, GASSILL MA, BADALONA E: Intracolonic administration of zlleuton, a selective 5-lipoxygenase inhibitor stricture formation and accelerates healing in a rat model of chronic colitis. Gastroenterology (1995) 108(4 Suppl.):A782.
   Google Scholar
• OKAYASU I, HATAKEYAMA S, YAMADA M, OHKUSA T, INAGAKI Y, NAKAYA R: A novel method in the induction of reliable experimental colitis in mice. Gastroenterology (1990) 98:694–702.
   PubMed Web of Science ®Google Scholar
• WARREN BF, WATKINS PE: Animal models of inflamma-tory bowel disease. J Pathol. (1994) 172:313–316.
   PubMedGoogle Scholar
• CLAPP NK: Natural history, time course and pathogene-sis of idiopathic colitis in cotton-top tamarins. In: A Primary Model for the Study of Colitis and Colonic Carci-noma, Clapp NK (Ed.), CRC Press, Boca Raton (1993).
   Google Scholar
• LUSBAUGH C, HUMASON G, MOPE H, CLAPP NK: Histol-ogy of colitis in marmosets. Dig. Dis. Sci. (1985) 30:45S–51S.
   Google Scholar
• CLAPP NK: Spontaneous colonic carcinoma. In: A Pn'-maiy Model for the Study of Colitis and Colonic Carcinoma, Clapp NK (Ed.), CRC Press, Boca Raton (1993).
   Google Scholar
• SNAPPER JR, CHRISTMAN BW: Models of acute pulmo-nary inflammation. Mod. Methods Pharmacol. (1989) 5:255–281.
   Google Scholar
• MORLEY J: Immunopharmacology of asthma. Immunol.Today (1993) 14:317–322.
   PubMedGoogle Scholar
• JACOBS RT, VEALE CA, WOLANIN DJ: Pulmonary and anti-allergy agents. Ann. Reports Med. Chem. (1992) 27:109–118.
   Google Scholar
• SHINDO K, FUKUMURA M, MIYAKAWA K: LTB4 levels inthe arterial blood of asthmatic patients and the effects of prednisolone. Eur. Respir. j. (1995) 8:605–610.
   PubMedGoogle Scholar
• YOUNG JM, DEYOUNG LM: Cutaneous models of inflam-mation. Mod. Methods Pharmacol. (1989) 5:215–231.
   Google Scholar
• NAGA() S, SEISHIMA M, MORI S, NOZAWA Y: Increased protein kinease C activity in fibroblast membranes from psoriatic patients. J. Invest. Dermatol. (1988) 90:406–408.
   PubMedGoogle Scholar
• MCCOL SR, HURST NP, BETTS WH, CLELAND LG: Modula-tion of human neutroplull LTA4 hydrolase activity by phorbol myristate acetate. Biochem. Btophys. Res. Corn-!nun (1985) 142:622–626.
   Google Scholar
• GROSS E, RUZICICA T: Epidermal eicosartoid receptors.In: Pharmacology of the Skin, Mulchtar H (Ed.), CRC Press, Boca Raton (1992).
   Google Scholar
• SUNDBERG JP, KENTY G, BEAMER WG, VENTURA AC, ADKINSON DL: Fore stomach papillomas in flaky skin and steel-Dickie mutant mice./ Vet. Diagn. Invest. (1992) 4:312–317 .
   PubMedGoogle Scholar
• SUNDBERG J, BOGGESS D, SUNDBERG B, BEAMER W, SHULTZ L: Epidermal dendritic cell populations in the flaky skin mutant mouse. Immunol. Invest. (1993) 22 :389–401.
   PubMed Web of Science ®Google Scholar
• KOCH K, MELVIN LS, REITER LA, BIGGERS MS, SHOWELL IIJ, GRIFPITHS RJ etal.: (+)-1-(3S,4R)43-(4-Phenylbenzy0-4-hydroxychroman-7-yncyclopentane carboxylic acid, a highly potent, selective LTB4 antagonist with oral activity. J. Med. Chem. (1994) 37:3197–3199.
   Google Scholar
• GRIFFITHS RJ, PETTIPHER ER, KOCH K, FARREL CA, BRES-
   Google Scholar
• •• LOW R, CONCKLYN MJ et al.: Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci, USA (1995) 92:517-521. Excellent effects of this compound, CP-105696, on joint histology.
   Google Scholar
• SHOWELL HJ, PETTIPHER ER, CHENG JB, BRESLOW R, CONKLYN MJ et al.: The in vitro and in vivo pharmacologic activity of the LTB4 antagonist CP-105696. J. Pharmacol. Exp. Therapeut. (1995) 273:176–184.
   PubMed Web of Science ®Google Scholar
• DAINES RA, CHAMBERS PA, EGGLESTON DS, FOLEY JJ, GRISWOLD DE, HALTIWANKER RC et al.: (E)-3-E6-(2-car-boxyetheny1)-5[[8-(4-methoxyphenyl-octylloxy]-2-pyridinyl]methyllthio]methyllbenzoic acid and related compounds: high affinity LTB4 receptor antagonists. J. Med. Chem. (1994) 37:3327–3336.
   PubMedGoogle Scholar
• YLI SS, DJURIC SW, DYGOS JH, TSAI BS, PAULSON SK, SMITH PF, FRETLAND DJ: SC-53228. Drugs Fut. (1994) 19:1093–1097.
   Google Scholar
• FRETLAND D, SANDERSON T, SMITH P, ADAMS L, CARSON R, FUHR J et al.: Oral efficacy of an LTB4 receptorantagonist in colitic cotton-top tamarins. Gut (1995) 37:702-707. Efficacy of SC-53228 in this disease model with spectacular effects on colonic histopathology.
   Google Scholar
• FRETLAND DJ, GOKHALE R, MATHUR L, BARON DA, PAULSON SK, STOLZENBACH J: Dermal inflammation in primates, mice and guinea pigs. Inflammation (1995) 19:333–346.
   PubMed Web of Science ®Google Scholar
• FRETLAND DJ, ANGLIN CP, WIDOMSKI DL, BARON DA,MAZIASZ T, SMITH PF: Pharmacological activity of the second-generation LTB4 receptor antagonist, SC-53228. Inflammation (1995) 19:503–515.
   PubMedGoogle Scholar
• PAULSON S, READUS Y, BULIK S, SCHOENHARD G, STOLZENBACH J, FRETI-AND D: The pharmacokinetics and metabolism of SC-53228. Inflam. Res. (1995) 44:S143–S144.
   Google Scholar
• FRETLAND D, ANGLIN C, BARON D, WIDOMSKI D, CHAUHAN K, BHATT R, FALCK J: 3(S)-Hydroxy LTB4 is a potent granulocyte chemotaxin in the guinea pig der-mis. Inflam. Res. (1995) 44:S137–5138.
   Google Scholar
• SHIRLEY M, MURPHY R, REIDHEAD C: Chemotactk LTB4metabolites produced by hepatocytes in the presence of ethanoL Biochem. Biophys. Res. Commun. (1992) 185:604–610.
   PubMedGoogle Scholar
• STEVENS WHM, VANDER-HEYDEN CP, WATTIE J, LANECG, SMITH WG, 0OBYRNE PM: Effect of LTB4 receptor antagonist, SC-53228, on ozone-induced airway respon-siveness in dogs. Am. J. Resp. Crtt. Care Med. (1995) 151:A350.
   Google Scholar
• SARAU HM, FOLEY JJ, SCHMIDT DB, TZIMAS MN, MARTINID et al.: SB 209247, a high affinity LTB4 receptor antagonist demonstrating potent anti-inflammtory ac-tivity. In: Advances in Prostaglandin, Thromboxane & Leuk-otriene Res., SamueLsson B, et. al., (Eds.), Raven Press, NY, (1995) 23: 275–277.
   Google Scholar
• MAIN AJ, BARSKY LI, MORRISSEY M, CADILLA R, BOEHM C, ZHANG Y et al.: Aryl amidines: anew class of potent orally active leukotriene B4 antagonist. 207th National Meeting of the American Chemical Society, March 13–17,1994, San Diego, USA: Abstr. MEDI 3.
   Google Scholar
• SAWYER JS, BALDWIN RF, SOFIA MJ, FOLREANCIG P, MARDER P, SAUSSY DL, FROELICH LL eta/.: Biphenyl-sub-stituted xanthones: highly potent leukotriene B4 recep-tor antagonists. J. Med. Chem. (1993) 36:3982–3984.
   Google Scholar
• COHEN N, BIZZARRO FT, MAY WP, TOTH K, LEE FK, HESL1N PH, LOLLAND GW, KWOH SC, FRANCO LS, SIMKO BA, YAGALOFF KA: Benzenepropanoic adds containing chromanone or naphthalenone moieties are potent and orally active leukotriene B4 antagonists. Bioorg. Med. Chem. Lett. (1994) 4:2883–2888.
   Google Scholar
• DJURIC SW, COLLINS PW, JONES PH, SHONE RL, TSAI BS,FRETLAND DJ, BUTCHKO GM, VILLANI-PRICE D, KEITH RH, ZEMAMS JM, METCALF L, BAUER RF: 743-(4-Acety1-3-methoxy-2-propylphenoxy)propoxy1-3,4-dihydro-8-propy1-2H-1-benzopyran-2-carboxylic add: an orally active selective leukotriene B4 receptor antagonist J. Med. Chem. (1989) 32:1145–1147.
   Google Scholar
• HUNG RE: Leukotriene receptor antagonists and biosyn-thesis inhibitors: potential breakthrough in asthma therapy. Eur. Respir. J. (1995) 8:1203–1213.
   PubMedGoogle Scholar
• UKACS NW, STRIETER RM, KUNKEL SL: Leukocyte infihra-tion In allergic airway inflammation. Am. J. Respir. Cell Mol. Biol. (1995) 13:1–6.
   PubMedGoogle Scholar
• OWE PM, LEE ML, JACKSON CJ, TO SS, COOPER AJ,SCHR1EBER L: The endothelium in psoriasis. Brit. J. Dermatol. (1995) 132:497–504.
   PubMedGoogle Scholar
• ANAUER SB, BAERT FJ: The management of ulcerative colitis. Annu. Rev. Med. (1995) 46:497-505. Excellent review of the state-of-art in IBD.
   Google Scholar
• DA H, KADOTA JI, KOHNO S, HARA K: Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest (1995) 108:116–122.
   PubMedGoogle Scholar
• EMLING RH: The modern version of adult respiratory distress syndrome. Annu. Rev. Med. (1995) 46:193–202.
   PubMedGoogle Scholar
• ONSTAN MW, WALENGA RW, HILLIARD KA, HILLIARD JB: Leukotriene B4 markedly elevated in the epithelial En-lug of patients with cystic fibrosis. Am. Rev. Respir. Dis. (1993) 148:896–901.
   PubMedGoogle Scholar
• EASMAN PA, COLLINS JG, OFFENBACHER S: Changes in crevicular fluid levels of 1L-1 beta, LTB4 and INF alpha In experimental gingivitis in humans. J. Periodontal Res. (1993) 28:241–247.
   PubMedGoogle Scholar
• OLE AT, SLATER K, SOKAL M, HAWKEY CJ: In vivo rectalInflammatory mediator changes with radiotherapy to the pelvis. Gut (1993) 34:1210–1214.
   PubMedGoogle Scholar